加载中
NASDAQHealthcareBiotechnology
最新数据
US$4.935
−US$0.335 · -6.36%
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
常规交易时段
US$4.935
−US$0.335 · -6.36%
盘中时间采用ET。市场数据可能有所延迟。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日内区间
当前US$4.935
52周区间
当前US$4.935
盘中时间采用ET。市场数据可能有所延迟。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日内区间
当前US$4.935
52周区间
当前US$4.935
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$33.67
上涨空间 582.27%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI582.13万0.00%2.3万亿 USD0.03%US$380.77-0.21%
iShares Russell 2000 ETFIWM225.12万0.00%787.4亿 USD0.19%US$276.04-0.67%
Vanguard Extended Market ETFVXF215.63万0.00%954亿 USD0.05%US$232-0.65%
Vanguard Russell 2000 ETFVTWO103.31万0.01%180亿 USD0.06%US$111.48-0.70%
iShares Russell 2000 Value ETFIWN82.27万0.01%137.49亿 USD0.24%US$210.13-0.46%
Dimensional - US Small Cap ETFDFAS53.79万0.00%338.04亿 USD0.31%US$77.915-0.33%
Fidelity Enhanced Small Cap ETFFESM49.38万0.01%64.1亿 USD0.28%US$44.99-0.55%
iShares Micro-Cap ETFIWC28.42万0.02%13.17亿 USD0.60%US$179.92-0.96%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
